Multi-omic profiling of human and mouse dorsal root ganglia enables targeted gene delivery to nociceptors
Brief intro:
- Author: Lily S. He, Parth Bhatia, Shamsuddin A. Bhuiyan, Evangelia Semizoglou, Jiaxiang Wang, Jia Li, Joohyun Nam, Jay X. J. Luo, Chayse Arnhold, Difei Zhu, Mengyi Xu, Dustin Griesemer, Hyo Jeong Yong, Lorna Jayne, Evangeline Gilmer, Qiyi Li, Katerina Pantaleo, Lite Yang, Erika K. Williams, Selwyn Jayakar, Brian J. Wainger, Sinisa Hrvatin, View ORCID ProfileWilliam Renthal, NIH PRECISION Human Pain Network
- Journal: BioRxiv
- Doi: https://www.doi.org/10.64898/2026.03.05.709931
- Publication Date: 2026/3/12
Abstract
Chronic pain conditions are often driven by hyperexcitability of nociceptors, the peripheral sensory neurons that detect noxious stimuli. Recent single-cell transcriptomic studies have begun to clarify the molecular identity of distinct peripheral sensory neuron subtypes, but tools that restrict transgene expression to nociceptors while sparing other dorsal root ganglion (DRG) subtypes remain limited. Here, we combined single-nucleus multi-omic profiling of human and mouse DRG with in vivo AAV enhancer screening to identify cis-regulatory elements that drive biased AAV expression in mouse DRG nociceptors and human iPSC-derived nociceptors. We then validated that an enhancer AAV designed to express Kir2.1 preferentially in nociceptors reduces DRG neuronal excitability. Leveraging these multi-omic datasets, we trained a sequence-based model to decode the cis-regulatory logic of nociceptors, enabling both the prioritization of native candidate elements and the design of synthetic enhancers with a range of nociceptor targeting properties. Together, these cross-species multi-omic resources define conserved DRG regulatory programs and provide a viral toolkit for pain research with potential translational applications for patients with refractory pain.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.